slides - hiv center
TRANSCRIPT
![Page 1: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/1.jpg)
Mark V. Bradley, M.D.Research Fellow, HIV Center for Clinical
and Behavioral Studies, New York State Psychiatric Institute and Columbia
University
HIV Center for Clinical and Behavioral Studies
Grand Rounds June 26, 2008
![Page 2: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/2.jpg)
The effectiveness of antiretroviral regimens depends upon high levels of patient adherence.
Treatment failure is predicted by poor adherence
High levels of adherence are required to ensure virologic suppression and prevent resistant strains (varies by regimen class type).
Most studies show that 40-60% of patients are less than 90% adherent
![Page 3: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/3.jpg)
Structural• Housing• Access to care• Financial resources• Transportation
Medication Regimen Characteristics• Complexity/Pill burden• Side effects
Individual-level factors• Education and health literacy• Physical symptoms• Use of avoidant coping strategies• Health beliefs• Psychiatric symptoms/disorders
![Page 4: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/4.jpg)
Substance use disorders Intravenous drug use Marijuana Cocaine use including crack Problem alcohol use Methamphetamine
“Serious mental illness”: psychotic illnesses and bipolar disorder
Anxiety disorders including PTSD
Depressive symptoms / disorders
![Page 5: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/5.jpg)
High prevalence of depressive disorders in HIV+ samples
Depression predicts poorer medical outcomes in HIV (Clinical progression, mortality), even after controlling for adherence
![Page 6: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/6.jpg)
Depression is a robust predictor of nonadherence across a range of studies and methodologies
Most of these studies have examined depression symptoms rather than categorical diagnoses.
Wagner et al, J Clin Epidemiol, 2001. 54 Suppl 1: p. S91-8.
Palepu et al, substance abuse treatment. Addiction, 2004. 99(3): p. 361-8.
Barfod et al AIDS Patient Care STDS, 2005. 19(5): p. 317-25.
Ammassari A., et al., Psychosomatics, 2004. 45(5): p. 394-402.
Arnsten et al, J Gen Intern Med, 2002. 17(5): p. 377-81.
Blanco et al, AIDS Res Hum Retroviruses, 2005. 21(8): p. 683-8.
Boarts et al, AIDS Behav, 2006. Carrieri et al., Int J Behav Med, 2003. 10(1): p. 1-14. Catz et al., Health Psychol, 2000. 19(2): p. 124-33. Gonzalez et al, Health Psychol, 2004. 23(4): p. 413-
8. Gordillo, et al Aids, 1999. 13(13): p. 1763-9. Murphy et al., Arch Pediatr Adolesc Med, 2005.
159(8): p. 764-70. Holzemer et al., AIDS Patient Care STDS, 1999.
13(3): p. 185-97. Reynolds et al., AIDS Behav, 2004. 8(2): p. 141-50. Tucker et al., Am J Med, 2003. 114(7): p. 573-80. Waldrop-Valverde et al, Patient Care STDS, 2005.
19(5): p. 326-34.
![Page 7: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/7.jpg)
Cardiac disease and diabetes research has also found that depression predicts poor medication adherence
Gehi, A., et al., Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med, 2005. 165(21): p. 2508-13.
Kalsekar, I.D., et al., Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents. Ann Pharmacother, 2006. 40(4): p. 605-11.
Lustman, P.J. and R.E. Clouse, Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications, 2005. 19(2): p. 113-22.
Barth, J., M. Schumacher, and C. Herrmann-Lingen, Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med, 2004. 66(6): p. 802-13.
![Page 8: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/8.jpg)
Two studies provide retrospective evidence that treatment of depression improves adherence in HIV+ populations (Yun et al, JAIDS 2005; Cook et al, AIDS Care 2006)
Research in other medical illnesses (diabetes, cardiocascular disease) have suggested prospectively and retrospectively that treating depression may improve adherence (Lustman, Arch Gen Psychiatry 2006; Katon et al, Arch Intern Med 2005 )
![Page 9: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/9.jpg)
• To date, no published prospective research has demonstrated that treating depression improves adherence in HIV-positive depressed, nonadherent medical patients.
• The symptom threshold for adherence problems is not known.
• The time from depression response to adherence improvement is not known.
• The specific components of depression symptomatology responsible for adherence failures are not known.
![Page 10: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/10.jpg)
Naturalistic design Following depressed, antiretroviral
nonadherent HIV+ clinic patients who have recently started or optimized treatment for depression
Monitoring their depressive symptoms and antiretroviral adherence as they continue antidepressant treatment.
![Page 11: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/11.jpg)
HIV+ adult patients Referred to study based on history of
depression and/or nonadherence Recent initiation or change in antidepressant
treatment (medication switch, titration, or augmentation) or initiation of psychotherapy
Followed in one of three HIV medical or mental health clinics at Columbia Med Ctr., or the Center for Special Studies at Cornell.
![Page 12: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/12.jpg)
Currently on antiretrovirals Meet the criteria for Major Depressive
Disorder, Minor Depressive Disorder, or Dysthymic Disorder (SCID)
Demonstrates <80% adherence at baseline Does not meet criteria for substance use
disorder in the past month Fluent in English No h/o bipolar disorder
![Page 13: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/13.jpg)
Adherence : • Chesney’s ACTG Follow-Up Questionnaire for
Adherence to Antiretroviral Medications • Visual Analog Scale • Pill Count• Viral load
Depression : • Hamilton Depression Scale• Depression Module of the SCID
![Page 14: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/14.jpg)
Substance use: HIV Center Substance Use Questionnaire (potential depression-nonadherence mediator)
Cognition:• Rey Verbal Learning Test• WAIS Letter-Number Sequence• Stroop• Color Trails A and B• Controlled Oral Word Association• WAIS Test of Adult Reading
![Page 15: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/15.jpg)
Assessment Time
Baseline assessment(0 weeks)
Follow up assessment 1(4 weeks)
Follow up assessment 2(8 weeks)
Measures -SCID
-Adherence measures
-HAM-D
-Substance use Questionnaire
-Demographics
-Brief Cognitive Battery
-Adherence measures
-Substance use questionnaire
-HAM-D
-Depression module of SCID
-Adherence measures
-Substance use questionnaire
-HAM-D
-Depression module of SCID
-Brief Cognitive Battery
![Page 16: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/16.jpg)
Linear regression models to examining associations between changes in adherence scores and changes in HAM-D scores, controlling for substance use at each time point.
Generalized estimating equations will be used to account for within-subject correlation across the three time points.
In secondary analyses, we will examine relationships between specific depression symptoms (such as depressed mood, insomnia, and anergia) and adherence
![Page 17: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/17.jpg)
Recruitment procedures commenced in November, 2007
Recruitment represented a major challenge to this study
The intersection of specific eligibility criteria in several domains resulted in many patients being screened out of the study:
• Depressive disorder • <80% adherent in past 4 days - 1 week• Recent onset/change in depression treatment• Fluent in English• Not actively using substances• No history of bipolar disorder• No psychotic symptoms
![Page 18: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/18.jpg)
Many patients identified and treated for depression demonstrate good adherence
Many patients systematically identified as nonadherent by their clinicians also demonstrate other exlusionary features, especially active substance use and comorbid psychopathology
![Page 19: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/19.jpg)
9 participants recruited to date
N %Gender 5 men
4 women5644
Ethnicity
African-American
4 44
White 3 33
More than one 2 22
Inclusion diagnosis
6 MDD3 Dysthymic
6633
Sexual orientation
5 straight4 gay
5644
Unmployed 8 89
![Page 20: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/20.jpg)
mean range
Baseline 21-item Hamilton
13.67 3-22
Baseline Adherence
69.3 52.5-80.5
![Page 21: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/21.jpg)
4 participants have completed to date. • These subjects have overall demonstrated some
evidence of improvement in adherence which occurred alongside improvements in depression scores
2 participants have not followed up after baseline due to re-emergent, severe substance use problems
3 participants remain in the process of data collection
![Page 22: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/22.jpg)
Baseline 4 weeks 8 weeks Subject HAM-
D ADH %
HAM-D
ADH %
Dep Dx
HAM-D
ADH %
Dep Dx
1 11 67.5 2 81.5 None 3 67.3 None 2 13 64.1 9 95 None 15 95 None 3 20 52.5 10 98 None 4 100 None 4 10 80.5 7 90.5 MDD 3 100 None Means 13.5 66.3 7 91.3 6.25 90.6
![Page 23: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/23.jpg)
Depressed, nonadherent HIV-positive patients demonstrate a degree of psychosocial complexity and comorbidity that makes recruitment challenging.
Studies designed to examine this population may require a degree of “tolerance” for this complexity, rather than highly restrictive eligibility criteria
![Page 24: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/24.jpg)
When substance use disorders are not an active issue, individual cases suggest that treating depressive disorders may be one method for improving adherence in depressed patients
Future research will require larger samples and longer follow-up periods in order to elucidate relationships between depression treatment and adherence changes.
![Page 25: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/25.jpg)
This study has been funded by the HIV Center’s Pilot Studies Program and
by the Columbia Department of Psychiatry Frontier Fund.
Dr. Bradley is supported by a training grant from NIMH (T32 MH19139;
Behavioral Sciences Research in HIV Infection; Principal Investigator,
Anke A. Ehrhardt Ph.D.; Training Director: Theo Sandfort, Ph.D.).
The HIV Center for Clinical and Behavioral Studies at the New York State
Psychiatric Institute and Columbia University is supported by a grant
from NIMH (P30-MH43520; Principal Investigator: Anke A. Ehrhardt Ph.D.).
![Page 26: Slides - HIV CENTER](https://reader033.vdocuments.site/reader033/viewer/2022052912/55a02ab21a28ab181f8b4611/html5/thumbnails/26.jpg)
MentorRobert H. Remien, PhDStudy AdvisorsJudith G. Rabkin, PhDMilton Wainberg, MDCheng-Shiun Leu, PhDHIV Center ExpertisePatricia Warne, PhDKatherine Elkington, PhDResearch AssistantElizabeth Arias, MA
Harkness-6Karen Brudney, MDNoga Shalev, MDAnne Skomorowsky, MDLucy Ann Wicks ClinicJoan Storey, PhDVera Smith, PhDAlexandra Bloom, PhDElizabeth Wade, PhDCenter for Special
StudiesTodd P. Loftus, MDJoseph F. Murray, MD